-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925

Benzinga·11/02/2026 13:52:02
Diffusion vocale
Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.